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espite the proven efficacy of antipsychotic med-
ications and despite the additional advantages of the new-
generation antipsychotics,
1-5 one-fifth to one-half of schiz-
ophrenia patients are classified as refractory to
pharmacological treatment
6-13 and this proportion remains
consistent over time.
3 The management of treatment-
refractory schizophrenia (TRS) is a persistent public
health problem,because a substantial number of inpatient
psychiatric beds
14 and resources are devoted to these
patients,
15 and because they experience the worst out-
comes,such as suicide
16 and homelessness.
17TRS can man-
ifest itself as failure to achieve remission from the initial
episode of psychosis,failure to maintain remission,or grad-
ual deterioration in the context of successive relapses.
18
For classification and descriptive purposes,as well as for
enrollment into trials of experimental treatments,TRS
patients are grouped on the basis of predefined criteria.
However, there is considerable variability within this
population, in terms of specific domain of treatment
refractoriness as well as degree of refractoriness (sever-
ity of persistent symptoms).
Defining treatment refractoriness
Since treatment with antipsychotic drugs has been the
most accepted and effective treatment intervention in
schizophrenia over the last 40 years,the traditional def-
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D
Between one-third and one-half of the individuals who
meet diagnostic criteria for schizophrenia remain actively
ill despite optimal pharmacological treatment. These indi-
viduals tend to progressively deteriorate in terms of social
and vocational functioning despite major public and pri-
vate investments in their rehabilitation. For patients who
do not respond to the first prescribed antipsychotic drug,
current clinical practice is to switch to a second and a
third drug, and eventually to clozapine, the only antipsy-
chotic drug proven to be effective in treatment-refrac-
tory schizophrenia (TRS). Occasionally, two antipsychotics
are given concomitantly or psychotropic drugs are added
to antipsychotic drugs; however, very few empirical data
exist to support this practice. Although there are many
exceptions, patients who do not benefit from the first
prescribed drug will not benefit from any pharmacolog-
ical intervention. Therefore, efforts are under way to
determine the reason for lack of response to available
treatments and devise novel, more effective treatments.
To be successful these efforts must result in a more spe-
cific definition of TRS, as well as in a better understand-
ing of the illness pathophysiology and the mechanism of
action of the drugs.
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This definition includes chronic illness and failure to
achieve a decline in Brief Psychiatric Rating Scale
(BPRS) score of between 20% and 30% despite two ade-
quate treatment trials with antipsychotics from two dif-
ferent classes.
19A 4- to 6-week trial of 400 to 600 mg/day
chlorpromazine or its equivalent is currently accepted as
the standard for an adequate treatment trial.
20-22
Interestingly, although the original definitions of TRS
require failure to respond to treatment with two drugs,
there is evidence that failure to respond to one drug is
strongly predictive of failure to respond to the second
drug.
23,24
Starting in the late 1970s and 1980s,the diagnostic sys-
tems (Diagnostic and Statistical Manual of Mental
Disorders [DSM] and International Classification of
Diseases [ICD]) have been continually revised to reflect
a more narrow definition of schizophrenia with psychosis
as a central feature.Interestingly,this corresponds to the
period when antipsychotic drugs have fully penetrated
daily clinical practice.No wonder,therefore,that treat-
ment success and treatment refractoriness were defined
as a function of these drugs’ ability to suppress psychotic
symptoms.During most of the 1990s,the focus of schizo-
phrenia research and treatment has moved from psy-
chosis towards enduring negative symptoms,
25,26 cognitive
impairment,
27-31 and recently,quality of life
32,33 and social
reintegration.
34-36 Interestingly,the more recent definition
of TRS has raised the bar to include the persistence of
moderate-to-severe positive and negative symptoms
together with the persistence of other symptoms such as
cognitive, social, and occupational impairments and
behavioral problems.
37,38This definition,in addition to the
expectation that the novel antipsychotics will distinguish
themselves from the classic ones and among themselves,
has changed treatment expectations and redefined treat-
ment outcome to encompass these domains.
Some of the difficulty associated with the definition of
TRS derives from the confusion between illness severity,
chronicity,and illness sequels.Using the broadest defin-
ition of TRS would imply that any persistence of any
symptom,or abnormal behavior or sequel,would qualify
for treatment refractoriness.For example,an adolescent
who before the first psychotic episode had been socially
and vocationally successful,but who has not returned to
the previous level of functioning despite adequate and
extensive treatment, could be considered as suffering
from TRS.
In summary,because of the syndromal nature of schizo-
phrenia,and the heterogeneous response to treatment,
classifying a patient or a cohort as TRS has little descrip-
tive or empirical value. For example, patients can be
defined as suffering from TRS for the purpose of enrol-
ment into an intervention trial, or for the purposes of
deciding the level of disability compensations and sup-
port need with activities of daily living (ADLs).Hence,
depending on the purpose of the definition,the criteria
for TRS must reflect the specific domain(s) of refrac-
toriness,its severity,and previous treatment attempts.
Mechanisms of TRS
Since it became clear that a significant proportion of
patients do not respond to available treatments,clinicians
and investigators attempted to predict nonresponse to
treatment as early as possible and explain the mecha-
nisms of TRS. However, this attempt has been fraught
with both scientific and conceptual difficulties.
Epidemiological data have revealed that male gender,
8,39,40
early age of onset of illness,
41-43 positive family history of
schizophrenia,
44,45 obstetric complications,
46 absence of
affective symptoms,
47 severe and lengthy premorbid man-
ifestations,
39,45,48,49 longer duration of untreated psy-
chosis,
50,51 severe negative and cognitive symptoms,
52,53
presence of soft neurological signs,early onset of abnor-
mal involuntary movements,
54 and low level of social
functioning
55 were all associated with some degree of
treatment refractoriness.However,the reported associa-
tions have generally been weak and inconsistent.
Furthermore,even if the associations were stronger and
more consistent, they would not necessarily constitute
early predictive markers or explanatory mechanisms
since too often they are epiphenomena, and conse-
quences of TRS.For example,poor social functioning in
an individual whose TRS illness started at an early age
before he or she had an opportunity to acquire social and
vocational skills is a result of the early and persistent ill-
ness,rather than an explanation or a predictor of TRS.
Ventricular
56-58 and cortical sulci enlargements
57,59,60
abnormal cell migration in the prefrontal cortex,
61 cavum
septum pellucidum,
62 and abnormal (lower) cere-
brospinal fluid (CSF)
63 and plasma catecholamine con-
centrations
64 are some of the biological markers associ-
ated with TRS.Unfortunately,most of these findings are
the result of post hoc subgroup analysis generally derived
from studies failing to demonstrate the a priori hypoth-
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most of the post hoc findings have not been consistently
replicated or demonstrated in a priori designed studies.
Despite the conflicting data—or maybe because of the
conflicting data—theoretical formulations have been
advanced to explain TRS.Both the developmental and
the degenerative conceptualizations of schizophrenia
have been invoked to explain TRS.
65 An immutable,
genetically mediated process or one mediated by an early
developmental insult can confer characteristics that are
not responsive to available treatment,but are not neces-
sary related to psychosis.For example,being born with a
medium-to-low intelligence quotient (IQ) would create
the impression of TRS in a psychotic patient,even after
the psychosis improves.Similarly,a degenerative process
might confer the refractoriness to treatment.In fact,TRS
very rarely develops after the first or second episode,but
rather after several episodes and several years of illness.
Only 10% to 15% of schizophrenia patients are treat-
ment refractory at the onset of disease,
8 while nearly one-
half eventually become treatment refractory. Taken
together with the imaging studies reporting progressive
degeneration of brain parenchyma in TRS patients,
66
these data are at least consistent with a degenerative
process.
While the biological mechanisms of TRS (like the mech-
anism of schizophrenia in general) remain elusive,there
are a number of environmental and conceptual explana-
tions for TRS.Poor compliance with drug treatment is a
frequent problem among schizophrenia patients. Side
effects such as extrapyramidal symptoms (EPS),sexual
dysfunction,and weight gain,
67-69 along with lack of insight
are the leading causes of noncompliance. Apparently,
physicians often underestimate the nonadherence of their
patients,which in turn does not allow them to consider
nonadherence as a probable explanation for treatment
refractoriness.Hence,some of the patients classified as
TRS may not actually be on medication.Use and abuse
of illicit drugs, alcohol, and prescription medications
(such as anticholinergic agents) might obscure,impede,
or diminish the therapeutic effect of antipsychotics,fur-
ther increasing the proportion of TRS patients.
Distinguishing between TRS, consequences, and com-
plications of illness, as well as non-illness–related mal-
adaptive behaviors further complicates the understand-
ing of TRS. For example, poor social adjustment due to
interruption of vocational training, stigma, and demor-
alization, poor hygiene, and unhealthy lifestyle all con-
tribute and add up to give the appearance of TRS.
Furthermore, a tendency to attribute any maladaptive
behavior, such as antisocial or deviation from cognitive
performance norms, to the schizophrenic illness in an
individual carrying a diagnosis of schizophrenia,further
enhances the appearance of TRS.For example,although
the premorbid distribution of cognitive performance
scores is mildly shifted to the left (worse) in schizo-
phrenic patients, and although for some individuals it
could be linked to the schizophrenic illness, the IQ dis-
tribution contains very severely impaired patients,
mostly individuals of average intelligence, as well as
some very intelligent patients.This is consistent with the
notion that some cognitive deficiencies are related to the
illness, while most others are not. Yet cognitive defi-
ciency, whenever present, is attributed to the schizo-
phrenic illness and pharmacological interventions are
targeted toward improving it.Furthermore,exaggerated
expression of normal frustration with the hurdles of
daily life is often viewed as illness-related aggression.
Failure to improve cognitive performance or altered
maladaptive behavior is often viewed as evidence for
TRS.Finally,even though various degrees of depressed
mood and anxious mood are very prevalent in patients
suffering from schizophrenia,they could be merely sec-
ondary to a daily struggle and frustration associated with
a chronic mental disease, rather than a primary mani-
festation of disease. Regardless of whether some or all
of these manifestations are an integral part of the schiz-
ophrenic illness, complications, or comorbidities, they
add to the appearance of TRS.
In summary,progress in defining the boundaries of TRS
and distinguishing between primary illnesses–related
manifestations and the complications and consequences
of illness might both improve the yield of treatment and
prevent unnecessary treatment. More important, the
solution to TRS is closely dependent on understanding
the biology of schizophrenia in general.Meanwhile,the
immediate treatment needs of TRS must be addressed
with the available knowledge and tools.
Treatment of TRS
Verifying compliance by measuring neuroleptic plasma
level or prolactin levels should be the starting point in the
treatment of a TRS patient. Reconsidering doses and
dosing should follow so that EPS and akathisia are not
confounded with TRS.Assessing and treating psychiatric
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63comorbidities and medical comorbidities should follow.
Nonpharmacological,social,family,and personal needs
that might affect illness manifestation and nonresponse
to treatment should be addressed.
70-73 Realistic treatment
targets,which consider the premorbid (often poor) func-
tioning, should then be set. It is essential to remember
that in an illness that is by definition chronic, such as
schizophrenia,response is a relative term and that many
patients continue to suffer from low-level symptoms even
after a significant response to treatment has occurred.
Biological treatment for TRS patients is centered on the
use of clozapine or newer atypical antipsychotics,aug-
mentation drug therapies, and the combination of
antipsychotics with electroconvulsive treatment (ECT).
These strategies have been well reviewed elsewhere
37,74,75
and thus will be briefly summarized here. However,
before reviewing each individual intervention,it is essen-
tial to consider the inherent difficulties in conducting tri-
als in TRS patients and hence providing good scientific
data to address this prevalent problem. Trials in TRS
patients are longer and more laborious,the population is
difficult to agree upon and even more difficult to recruit.
More importantly, when strategies in which an active
compound or placebo is added to an antipsychotic
(adjunctive therapy or augmentation) are evaluated,the
sample size necessary to obtain valid results is extremely
large—a fact that further increases the effort and the cost
of the trial.
76
Moreover,due to pharmacokinetic interactions,add-on
trials present difficulties in interpreting the results.It is
often difficult to determine whether the advantage of the
added compound is due to an intrinsic property of the
added compound or due to changing the blood concen-
tration of the concomitantly administered medication.
Because of the difficulties conducting prospective trials
in TRS patients, clinicians often base their practice on
consensus algorithms. Unfortunately, these algorithms
are too often based on impressionistic data rather than
on randomized clinical trials.
Clozapine
Despite some recent reservations,clozapine remains the
gold standard for the treatment of TRS,being the only
drug with proven superiority to both chlorpromazine in
rigorously defined TRS
19 and other classic neuroleptics.
21,77
Furthermore, clozapine was found to be effective in
reducing violent behavior,
78,79 and the risk of suicide.
16,80,81
Nevertheless,a recently published meta-analysis suggests
that,despite its reputation,most recent studies did not
support the superiority shown by clozapine in early tri-
als.
82 Furthermore,although more TRS patients benefited
from clozapine compared with previous antipsychotic
treatment,between 50% and 70% of the TRS patients
did not significantly benefit from the switch to clozap-
ine.
42,83 In particular,most recent trials indicated that the
differential reduction in BPRS scores favoring clozapine
was very small and of questionable clinical significance.
Additional remarks on treatment with clozapine are
noteworthy.Some of the benefits of treatment with cloza-
pine become evident on long-term follow-up.Some stud-
ies have shown that a subset of TRS patients need longer
periods than the usual 6 to 8 weeks of adequate dose
84,85
to show a significant response.
16,42,86 Furthermore,patients
who do not respond under a regular dose may respond
to high doses that bring their plasma level higher than
350 ng/mL.
87
A still unresolved question is whether clozapine does
indeed have unique intrinsic proprieties that make it
effective in TRS or whether its higher efficacy over the
classic antipsychotics is secondary to its better tolerabil-
ity (no EPS and an upper ceiling for doses). In fact, the
possibility that clozapine might have unique intrinsic
properties that confer its advantage over the rest of the
antipsychotics has generated a large number of investi-
gations to elucidate its mechanism of action.Its relatively
weaker affinity for,and lower occupancy of,nigrostria-
tum dopamine D2 receptors, its D2/5-HT2 (serotonin
receptor) ratio, its anticholinergic and cholinomimetic
activities,as well as its selectivity for putative brain areas
have all been suggested to explain clozapine’s unique
clinical properties. Despite the fact that no agreement
exists as to what mechanism mediates clozapine’s unique
clinical profile, most of the novel antipsychotic drugs
were modeled on it.
Novel atypical agents
The availability of a generation of novel antipsychotics
modeled on clozapine has raised expectations that they
will be effective in treating TRS. In fact, many of the
patients who were treated with the novel drugs were ini-
tially partial responders or TRS patients.Studies showed
better efficacy of risperidone,
88-90 olanzapine,
91-95 quetiap-
ine,
96 and recently ziprasidone
97 in TRS patients or par-
tial responders compared with typical agents.However,
Pharmacological aspects
64the differential efficacy was modest,
5,98 some of the stud-
ies had methodological limitations such as less rigorous
definitions of TRS
91-94,99-101 and of what constitutes
response, open-label and retrospective designs,
88,89 and
small sample size.
99-101A corollary attempt to examine if
the novel antipsychotics are effective in TRS patients was
to treat aspects of schizophrenia that tend not to respond
to classic drugs,such as the negative symptoms and the
cognitive impairment.Initial results have suggested an
advantage for cognitive impairment
29,102-105 and for nega-
tive symptoms,
95,106-110 but these advantages have not been
consistent across trials.
19,42,86,111-114 
Combined antipsychotic drugs
The assumption that broader or higher level of receptor
binding could lead to improved efficacy of antipsychotics
constitutes the rationale behind the use of combined
antipsychotic therapy.While the use of this approach is
growing along with the frequent use of polypharmacy in
schizophrenia patients (estimated 20%),
115 little research
is available to support it.The data derive mostly from
case reports and open studies indicating improved effi-
cacy of clozapine treatment following the addition of
risperidone,
116-122 olanzapine,
123 or typical agents,such as
pimozide and sulpiride.
124-126 However, the rationale
behind this strategy remains elusive and the supportive
data are doubtful. Selecting polypharmacy regimens
according to specific symptoms or on the basis of a puta-
tive mechanism of action is way ahead of the current
state of basic knowledge of schizophrenia pathophysiol-
ogy and the recognized mechanism of action of drugs.
Furthermore, occasionally, the rationale for combined
antipsychotic treatment contradicts the current theories
on mechanisms of action of drugs.Such is the case with
the use of adjunctive antipsychotics and clozapine.While
some of the presumed advantages of clozapine are
related to its limited D2 antagonism,prescribing adjunc-
tive antipsychotics transforms clozapine into a classic
drug.
Antidepressants
Since depressed mood, residual depression, or even
demoralization are often taken as unsatisfactory
response to treatment,antidepressants are extensively
used as adjunctive treatment to antipsychotics in schizo-
phrenia.Most of the data on the use of antidepressants
are derived from trials with selective serotonin reuptake
inhibitors (SSRIs), which have occasionally,
127-131 but
inconsistently,
132 showed efficacy.At present,there is no
convincing evidence to support or refute the use of anti-
depressants in treating depression in schizophrenia
133,134
and no substantial evidence to support the use of these
agents for the treatment of refractory negative symp-
toms.Furthermore,the question of whether it is possible
to distinguish between comorbid major depression,
depressive symptoms, demoralization, anhedonia, and
persistent negative symptoms remains open.
Mood-stabilizing drug treatments
Most of the data on adjunct medications are on lithium
and anticonvulsants.Several studies indicated a benefi-
cial effect of lithium in TRS patients.
135-138 However,these
studies used loose definitions of TRS and small samples.
Definitive evidence of a significant efficacy of lithium has
not been presented yet.This could be because the pre-
liminary trials are not sufficiently encouraging or because
there is no sufficient commercial incentive to invest in a
large (expensive) trial to provide definitive evidence.
Studies on anticonvulsants as adjunct therapy for TRS
yielded contradicting findings on valproic acid
139,140 and
modest effects in controlled studies with small samples
on adjunct carbamazepine.
16,141,142 Data on novel anticon-
vulsants (topiramate and lamotrigine) is limited to case
studies.
143While anticonvulsants are widely used,there
are few controlled trials on their efficacy.Furthermore,
anticonvulsants and lithium are prescribed for violent
behavior, although evidence is scarce. Unlike the pur-
poseless violence in temporal lobe epilepsy,there is no
reason to believe that violence in schizophrenia has a
specific illness-related biological mechanism. If carba-
mazepine can be effective in treating the violent outburst
of TRS,this is probably the result of a nonspecific non-
illness–related effect.Hence,it is essential to demonstrate
first that the drug is effective in treating violence across
diseases as well as primary violence before using it in
TRS.
Electroconvulsive therapy
ECT given concomitantly with antipsychotic drugs was
shown to have some effect on TRS in a few short-term
trials and case reports.
144-151 However, it is important to
note that patients who get ECT are the more severe
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Conclusions
TRS remains a major personal tragedy and a public
health problem. However, because so little is known
about TRS and because the results of treatment are so
variable,it is essential to weight carefully the risk-benefit
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tolerated than older drugs and may be more effective in
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exists for TRS.It is essential that,instead of increasing the
dose and relentlessly adding and changing medications,
or embarking upon unproven interventions,psychiatrists
acknowledge to themselves and explain to frustrated
patients and family members,the limits of pharmacolog-
ical treatment. Otherwise, we run the risk of making a
bad situation worse by adding the suffering of adverse
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Hopefully, persistent investigation should lead us to
where other medical disciplines are,by which putative
drugs developed based on pathophysiological under-
standing will treat specific manifestations of this syndro-
mal disease. ❏
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Esquizofrenia resistente al tratamiento
Entre un tercio y la mitad de los individuos que
cumplen con los criterios diagnósticos para esqui-
zofrenia permanecen con la enfermedad activa a
pesar de un tratamiento farmacológico óptimo.
Estos sujetos tienden a deteriorarse progresiva-
mente en términos del funcionamiento social y
vocacional a pesar de las grandes inversiones públi-
cas y privadas en su rehabilitación. Para los pacien-
tes que no responden al primer fármaco antipsicó-
tico prescrito, la práctica clínica actual consiste en
cambiar a un segundo y a un tercer fármaco, o
como último recurso en administrar clozapina, el
único fármaco antipsicótico que ha probado ser
efectivo en la esquizofrenia resistente al trata-
miento (ERT). En ocasiones se han indicado dos
antipsicóticos en forma simultánea o se han agre-
gado otros psicotrópicos a fármacos antipsicóticos;
sin embargo, existen muy pocos datos empíricos
que sustenten esta práctica. Aunque hay muchas
excepciones, los pacientes que no se benefician con
el primer fármaco prescrito tampoco se beneficia-
rán con alguna otra intervención farmacológica.
Por lo tanto, los esfuerzos deben orientarse a deter-
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